

**Table 3.** The ASPNE survey results before the initiation of treatment and after 12 months of anti-fibrotic therapy with pirfenidone

Patient needs and expectations	Before pirfenidone treatment (baseline)	After 12 months of pirfenidone treatment	p value
1. Life extension regardless of its quality	3.96 ± 1.50	3.96 ± 1.37	0.13
2. Complete and reliable information about the disease, its cause, and prognosis	4.39 ± 1.10	4.35 ± 1.10	0.89
3. Fast and easy access to health centres specializing in IPF treatment	4.70 ± 0.58	4.77 ± 0.60	0.21
4. Improvement of comfort and quality of life or maintaining its level	4.65 ± 0.75	4.71 ± 0.92	0.29
5. Decrease of cough intensity	4.00 ± 1.39	4.02 ± 1.41	0.99
6. Decrease of dyspnoea discomfort	3.92 ± 1.35	4.30 ± 1.13	0.31
7. Improvement of the general condition or the maintenance of its level	4.7 ± 0.74	4.73 ± 0.70	0.83
8. Access to novel therapy	4.84 ± 0.51	4.86 ± 0.46	0.56
9. Access to oxygen therapy at home	3.37 ± 1.70	3.58 ± 1.65	0.95
10. Easy access to reference centres	3.41 ± 1.58	3.69 ± 1.55	0.73
11. Stay self-dependent	4.47 ± 1.12	4.58 ± 1.05	0.22

12. Psychological support	2.92 ± 1.55	3.15 ± 1.56	0.66
13. Everyday social assistance	2.27 ± 1.45	2.74 ± 1.65	0.15
14. Well-tolerate pharmacological treatment	4.49 ± 0.82	4.67 ± 0.75	0.12
15. The right of deciding on disease management	3.96 ± 1.37	4.19 ± 1.12	<b>0.014</b>
Total	58.14 ± 13.81	61.71 ± 11.28	0.08

Data presented as mean ± SD.